PI Industries Q4 FY26: Holding Margins in a Downcycle, While Building the Next Growth Curve

PI Industries ended Q4 FY26 in a tougher global operating environment, with performance shaped by a volatile agrochemical cycle and customer delivery schedules. Consolidated revenue fell to INR 15,652 million, down 12 percent year on year. EBITDA declined 26 percent to INR 3,373 million, and profit after tax came in at INR 2,002 million, down 39 percent. Despite the earnings contraction, gross margin expanded to 58 percent from 55 percent last year, showing that product mix and cost discipline continued to work in the company’s favor.

For the full year, FY26 revenue was INR 67,137 million, down 16 percent. EBITDA was INR 17,053 million, down 22 percent, while PAT was INR 13,208 million, down 20 percent. The backdrop matters. Management positioned the year as a period of navigating the downcycle while building the next growth curve, leaning on a strong balance sheet, ongoing capex, and an R and D engine that is meant to keep the pipeline replenished. The company also highlighted operating cash flow of INR 4,740 million for FY26.

The quarter showed the familiar pattern of PI’s model in a weak export market: top line pressure, but an effort to preserve margin structure. Exports remained the main driver but were soft, while domestic brands saw a mild decline amid pricing pressure and regulatory transitions in biologics.

Q4 FY26: Exports down, domestic softer, mix supports gross margin

The export business, which remains the larger contributor, declined in Q4 FY26 to INR 12,585 million from INR 14,488 million, a drop of about 13 percent. The company attributed this to a contraction in the global agrochemical industry and a customer delivery schedule that kept shipments lower during the quarter.

Domestic revenue fell to INR 3,067 million from INR 3,383 million, down about 9 percent. The company noted that volumes were up about 3 percent, but elevated channel inventories and pricing pressure offset that. It also pointed to a reduction in key crop acreages and a regulatory transition in biologics that moved toward normalization, with flat growth for biologics in Q4.

One bright spot was Pharma, where revenue rose 23 percent year on year in Q4 to INR 1,048 million. Management said Pharma contributed roughly 8 percent of exports revenue in the quarter. This segment is still loss making at the PBT level, but the loss narrowed.

Financial summary

The gross margin improvement stood out because it came in a quarter where revenue was under pressure. PI linked it to favorable product mix and cost discipline. Overheads rose 8 percent to INR 5,684 million, which the company said reflected strategic development of newer businesses and new product promotion.

The tax rate also moved higher due to a higher share of business from non SEZ operations. The company indicated FY26 ETR at around 22 percent.

A shareholder friendly detail was the final dividend approval for FY25-26 of INR 10 per share, taking total dividend for the year to INR 15 per share including the interim dividend.

FY26: Profitability holds up, even as the cycle turns

FY26 was a year of lower revenue but still resilient profitability. Gross margin improved sharply to 58 percent from 53 percent, while EBITDA margin slipped to 25 percent from 27 percent. Management described the 25 percent EBITDA margin as in line with guidance, supported by product mix and operating efficiencies.

Exports declined from INR 65,794 million in FY25 to INR 54,117 million in FY26. Domestic revenue was more stable but still down, moving from INR 13,984 million to INR 13,020 million. The company said agchem exports declined 19 percent year on year, with volume down about 14 percent, after several years of strong growth and a high base effect.

The domestic business was affected by adverse weather, lower crop prices, regulatory disruption in biologics, and elevated channel inventories. Management also emphasized the role of new product launches in keeping the portfolio refreshed. PI commercialized 5 new molecules in exports and launched 4 products in domestic agri brands during FY26. New products contributed 18 percent of agchem exports revenue.

The year’s net profit included an exceptional income related to a writeback of contingent consideration of INR 1,260 million, partially offset by an additional provisioning of INR 229 million linked to the new labor code.

Balance sheet and cash: Flexibility to invest through the cycle

PI’s balance sheet remained a strategic asset in FY26. As of March 2026, shareholders’ funds stood at INR 112,305 million and cash, bank, and investments were INR 35,094 million. Debt levels remained low, with short term debt at INR 893 million. The company highlighted surplus cash net of debt of INR 34,265 million, which provides room for strategic investments.

Capex stayed elevated. Total capex for FY26 was INR 11,508 million, up from INR 9,280 million in FY25. This was positioned as continued investment in manufacturing capabilities to meet future customer requirements and to support R and D and new molecule innovation.

Working capital remained stable quarter on quarter, with net working capital days shown at 139 in both Q3 FY26 and Q4 FY26. Inventory days improved from 69 to 66, receivable days were steady at 126, and payable days reduced from 60 to 53.

On longer term compounding, PI’s five year CAGR numbers still show a business that has expanded meaningfully despite cyclical volatility. Revenue CAGR over five years was 8.0 percent, EBITDA 10.9 percent, and PAT 12.3 percent. Fixed assets grew at a 15.8 percent CAGR, reflecting sustained reinvestment.

Strategic building blocks: Pipeline, Pharma, Biologicals, and deeper technology

PI’s strategy in the presentation was framed as building the next growth curve while the core cycle remains weak. The company positioned itself as a differentiated partner to global innovators across the agchem value chain, with a non conflicting model spanning discovery, development, scale up, manufacturing, regulatory services, and marketing and distribution.

A core element is the R and D engine. PI reported more than 700 scientists including over 200 doctorates, more than 250 patents to date, and 43 patents in FY26. It also cited more than 90 projects at different development stages and an active pipeline of more than 90 molecules, with more than 60 percent in advanced stages. The company also stated that it filed for registration for Pioxanilippro.

On manufacturing strength, PI highlighted 15 fully automated multipurpose plants spread across five locations, distributed control systems, experience across more than 130 unit processes including hazardous chemistry, and capex underway with three multipurpose plants under construction. It also called out technology directions such as flow technology and vapor phase.

Pharma is the most visible diversification lever in the numbers. FY26 pharma revenue rose 40 percent year on year to INR 3,005 million, while PBT loss narrowed to INR 785 million from INR 2,494 million. The company described a shift in customer base toward an integrated CRDMO platform. It also highlighted capability building steps, including filing for regulatory approval of a GMP kilo facility in Lodi, establishing a center of excellence for drug discovery at its Hyderabad CRO facility, and developing a QC lab in Lodi along with computational tools.

Biologicals was presented as moving from foundation to acceleration. PI cited the launch of Harpinαβ in India, and noted that a bionematoicide registration was granted by the EPA in the US. It also pointed to planned proprietary brand launches east of the Rockies for the bionematoicide and a biostimulant, and distribution expansion in Mexico through onboarding a major national distributor. The company stated that global biologicals revenue excluding India is annualized at around USD 12 million with healthy margin upward of 60 percent, and expected to grow in double digits.

Outlook: A cautious bridge to FY27 growth

Management’s outlook balanced near term uncertainty with medium term confidence. For domestic, it flagged climatic uncertainty going into the Kharif season, though higher reservoir levels may partly mitigate this. It also pointed to input cost pressure from geopolitical tensions, and noted that adoption of new products is helping sales. The biologics business was described as on revival mode as regulatory normalization progresses.

For exports, PI guided to 5 or more new molecules to be launched in FY27, expected to accelerate growth, and expressed cautious optimism for the second half of FY27 based on committed customer offtake plans. It also said a strong order book continues to support FY27 growth outlook.

In Health Sciences, the company pointed to momentum from strategic partnerships entered in the last 12 months and improving visibility in business development and R and D pipeline over the next one to two years. It also highlighted expansion and enhancement of the GMP site in Lodi, Italy, alongside non GMP sites in India.

It also indicated that commercialization of PI’s own NCE is expected in FY27, with additional leads progressing through its partnership model. Inorganic growth opportunities were said to be under evaluation to complement long run growth.

Investor takeaways: Margins protected, capacity built, and multiple levers for the next cycle

PI Industries’ Q4 FY26 numbers reflect a downcycle in global agchem, but the underlying operating model still showed its key feature: gross margin resilience. Revenue and earnings declined sharply, yet the company stayed within its EBITDA margin guidance for the full year and continued to invest through the cycle.

For investors, the story hinges on three things. First, the core export engine depends on customer delivery schedules and the pace of global inventory normalization, but new molecule commercialization remains active. Second, domestic agri brands are facing channel and pricing pressure, yet new launches and digital led distribution reach provide a base to recover when the channel clears. Third, the next growth curve is being built through Pharma CRDMO and global biologicals, both of which showed traction in FY26 even if profitability is still evolving.

With surplus cash net of debt at INR 34,265 million and capex of INR 11,508 million in FY26, PI appears positioned to keep investing until volumes return. The near term remains uncertain, but the company’s outlook for FY27 suggests that the cycle may be setting up for improvement, supported by new launches, a strong order book, and expanding capabilities in new platforms.